The recall was related to syringes in these lots malfunctioning.
Adamis Pharmaceuticals is voluntarily recalling certain lots of Symjepi (epinephrine) injection, which is used for the emergency treatment of allergic reactions, including anaphylaxis to stinging insects and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis.
The lots impacted by the recall include 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 mL) pre-filled single-dose syringes. The products are packaged in two per carton and were distributed nationwide and directly to customers and/or medical facilities. The products can be identified by the label containing the US WorldMeds name and logo pictured on the cartons below. US WorldMeds markets and distributes Symjepi in the United States, under license from Adamis.
The recall was related to syringe malfunctioning in these lots. Although not confirmed to be related to the recall, there have been two customer complaints on three syringes, regarding difficulty in dispensing the product. The companies are not aware of any adverse events related to this recall.
The lots impact by the recall are:
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More